Long-term outcome and prognostic factors of single-dose Radioiodine Therapy in patients with Graves' disease
| Autor: | Feng-Chih Shen, Jung-Fu Chen, Chia-Jen Tsai, Chen-Kai Chou, Cheng-Feng Taso, Yi-Ting Yang, Chih-Min Chang, Pei-Wen Wang, Shih-Chen Tung, Ming-Chun Kuo, Shao-Wen Weng |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
medicine.medical_specialty Asia Goiter endocrine system diseases Graves' disease Taiwan Disease Tertiary referral hospital Iodine Radioisotopes 03 medical and health sciences 0302 clinical medicine Internal medicine hemic and lymphatic diseases Radioiodine therapy medicine Humans Retrospective Studies Outcome Univariate analysis lcsh:R5-920 business.industry Retrospective cohort study General Medicine Middle Aged Prognosis medicine.disease Graves Disease Regimen Treatment Outcome Goiter size 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology business lcsh:Medicine (General) |
| Zdroj: | Journal of the Formosan Medical Association, Vol 119, Iss 5, Pp 925-932 (2020) |
| ISSN: | 0929-6646 |
| Popis: | Background/purpose: Few studies exist investigating the effectiveness of radioiodine (RAI) therapy for hyperthyroidism patients in Asia. We herein investigated the real-world efficacy of single-dose RAI therapy in Taiwanese patients with Graves’ disease (GD). Methods: This is a retrospective study of 243 patients with GD recorded between 1989 and 2016 in a tertiary referral hospital. Eu- or hypothyroid after RAI therapy were defined as the successful group. Kaplan–Meier curve and cox-regression model were used for analysis of prognostic factors. Results: Of the 243 patients, 187 were females, with mean age of 46.9 ± 13.6 years. Most patients (63.8%) did not choose RAI as the first-line therapy. The median dose was 7 mCi, with a mean follow-up period of 107.1 ± 82.8 months. The overall success rate was 70.9%. Univariate analysis revealed calculated- or fixed-dose (P = 0.015), goiter size (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|